Adam S. Kittai

Dec 31, 2024 | mdpi.com | Adam S. Kittai

5.1.2. Covalent BTK Inhibition with and Without ChemoimmunotherapyBruton’s tyrosine kinase (BTK) has been implicated in the pathogenesis of B-cell lymphomas through its role in the B-cell receptor (BCR) signaling cascade, providing a strong rationale for its inhibition as a therapeutic strategy [32]. The covalent BTK inhibitors (cBTKis) have transformed the treatment paradigm of CLL, prompting interest in their potential use in RT.

Nov 6, 2024 | nature.com | Adam S. Kittai |Antonio Gutierrez |Antonio Gutiérrez |Alejandro Martín García-Sancho |Monica D. Mead |Pere Barba | +2 more

The rationale for this project arises from some considerations. Clinical trials often use surrogate endpoints (response rates) rather than direct measurement of benefit (survivals) as primary objective of the study.

Mar 29, 2024 | ascopubs.org | John Byrd |Adam S. Kittai |David Bond |Emily Blyth

We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80).

Feb 19, 2024 | nature.com | Adam S. Kittai |Jennifer A. Woyach

Karyotype complexity is established by enumerating the number of chromosome abnormalities present in a karyotype. In chronic lymphocytic leukemia (CLL), karyotype complexity, typically defined as ≥3 chromosome abnormalities, is an important prognostic indicator associated with poor outcomes [1]. Additionally, stratifying patients by highly complex karyotypes (≥5 chromosome abnormalities) has shown significantly poorer outcomes compared to patients with 3–4 abnormalities [2].

Oct 11, 2023 | onclive.com | Adam S. Kittai

Adam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) vs zanubrutinib (Brukinsa) monotherapy in treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), as seen in the phase 3 ELEVATE-TN (NCT02475681) and SEQUOIA (NCT03336333) trials.